Full-Time

Quality Assurance Specialist 1

Acm

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Madison, WI, USA

In Person

On-site role in Madison, Wisconsin; no remote option stated.

Category
QA & Testing (1)

Get referred to PCI Pharma Services

See people who can refer or advise you

Requirements
  • High school Diploma, GED, or equivalent credential required, AS degree or BS degree in Life Sciences or related field preferred.
  • 1-3 years of experience in Quality Assurance, aseptic processing, or cleanroom functions within a cGMP‑regulated environment; equivalent combination of education and experience will be considered
  • Ability to learn aseptic techniques, contamination control, and cGMP regulations (21 CFR Parts 210/211, EU Annex 1).
  • Demonstrated ability to observe critically and document behaviors accurately and objectively.
  • Excellent verbal and written communication skills; must be comfortable providing real-time coaching.
  • Ability to gown for entry into ISO 5, 6 and 7 cleanroom environments and remain in those areas for extended periods.
Responsibilities
  • Review operator’s aseptic behavior within the ISO 5 core and adjacent classified areas and escalate any concerns to the operator or their supervisor.
  • Observe and document real-time activities during manufacturing operations, including setup, filling, environmental monitoring, sanitization and routine/corrective interventions.
  • Ensure compliance with PCI aseptic technique expectations, gowning standards, and cleanroom behavior as outlined in SOPs and training.
  • Identify and escalate deviations from aseptic practices, personnel behaviors, or environmental controls that pose potential contamination risks.
  • Capture detailed and objective records of events, interventions, and nonconformances using PCI-approved documentation tools or checklists.
  • Support media fill (aseptic process simulation) operations by providing visual monitoring and feedback throughout the process.
  • Collaborate with Quality Assurance, Operations, Microbiology, and Training to identify opportunities for coaching, retraining, and continuous improvement.
  • Participate in contamination control and environmental monitoring trending to drive site-level improvements and reduce contamination risk.
  • Assist with investigations and root cause analysis for contamination events, EM excursions, and aseptic technique deviations.
Desired Qualifications
  • Proficient in Microsoft Office and electronic quality systems (preferred).
  • Prior experience in a QA or manufacturing oversight role at PCI or a similar aseptic operation is strongly preferred.

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Get referred to PCI Pharma Services

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • San Diego’s 2028 line more than doubles RTU syringe and cartridge capacity.
  • Bedford’s line reaches 33 million annual vial units, strengthening sterile supply.
  • Autoinjector capacity exceeds 250 million units annually after the 2027 line.

What critics are saying

  • San Diego capacity arrives only in first-half 2028, leaving competitors more immediate supply.
  • Large sterile buildouts create execution risk from validation, yield, and regulatory delays.
  • Customer concentration can strand expensive capacity if programs are delayed or cancelled.

What makes PCI Pharma Services unique

  • PCI combines sterile fill-finish, device assembly, packaging, and cold-chain support.
  • San Diego and Bedford add specialized capacity for prefilled syringes, vials, and lyophilization.
  • Phased U.S. and European investments target clinical-through-commercial drug-device programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.